Rural Health
Resources by Topic: Illicit drug use
Controlled Substance Prescribing Patterns Among Fatal Overdose Decedents with an Opioid, Stimulant, or Both Contributing to Death — Pennsylvania, 2017–2022
Reports on deaths involving opioids without stimulants, deaths involving stimulants without opioids, and deaths involving both opioids and stimulants in Pennsylvania between 2017 and 2022. Includes data for rural and urban areas. Discusses the role of opioid prescribing on overdose deaths.
Author(s): Stephanie Hayden, Stanley M. Murzynski, Ashley Bolton, Carrie Thomas Goetz
Citation: MMWR (Morbidity and Mortality Weekly Report), 74(12), 205-209
Date: 04/2025
Sponsoring organization: Centers for Disease Control and Prevention
view details
Reports on deaths involving opioids without stimulants, deaths involving stimulants without opioids, and deaths involving both opioids and stimulants in Pennsylvania between 2017 and 2022. Includes data for rural and urban areas. Discusses the role of opioid prescribing on overdose deaths.
Author(s): Stephanie Hayden, Stanley M. Murzynski, Ashley Bolton, Carrie Thomas Goetz
Citation: MMWR (Morbidity and Mortality Weekly Report), 74(12), 205-209
Date: 04/2025
Sponsoring organization: Centers for Disease Control and Prevention
view details
The Rural and Urban Supply of Clinicians With a DEA Waiver to Prescribe Buprenorphine in 2022 Prior to the Elimination of the Waiver Requirement
Report explores the differences in rates of clinicians with DEA waivers to prescribe buprenorphine in 2022 in rural versus urban counties. Highlights the rural gaps in access to buprenorphine to treat opioid use disorder prior to the elimination of the DEA waiver requirement in 2023. Provides rural, urban, and regional comparisons.
Date: 04/2025
Sponsoring organization: WWAMI Rural Health Research Center
view details
Report explores the differences in rates of clinicians with DEA waivers to prescribe buprenorphine in 2022 in rural versus urban counties. Highlights the rural gaps in access to buprenorphine to treat opioid use disorder prior to the elimination of the DEA waiver requirement in 2023. Provides rural, urban, and regional comparisons.
Date: 04/2025
Sponsoring organization: WWAMI Rural Health Research Center
view details
Medicare Beneficiary Receipt of Methadone by Drive Time to Opioid Treatment Programs
Examines availability of methadone at opioid treatment programs for Medicare beneficiaries who have been diagnosed with an opioid use disorder. Utilizes data from 640,706 Medicare beneficiaries and analyzes their respective drive time to a treatment facility as well as receipt of methadone treatment. Includes U.S. map showing locations of opioid treatment programs and rural versus urban comparisons of patient drive times.
Author(s): Jonathan Cantor, Helin G. Hernandez, Aaron Kofner, et al.
Citation: JAMA Network Open, 8(4)
Date: 04/2025
view details
Examines availability of methadone at opioid treatment programs for Medicare beneficiaries who have been diagnosed with an opioid use disorder. Utilizes data from 640,706 Medicare beneficiaries and analyzes their respective drive time to a treatment facility as well as receipt of methadone treatment. Includes U.S. map showing locations of opioid treatment programs and rural versus urban comparisons of patient drive times.
Author(s): Jonathan Cantor, Helin G. Hernandez, Aaron Kofner, et al.
Citation: JAMA Network Open, 8(4)
Date: 04/2025
view details
Barriers and Facilitators to Scaling up Medications for Opioid Use Disorder in Kentucky: Qualitative Perspectives of Treatment Organization Staff
Examines perspectives from substance use treatment program staff related to the barriers and facilitators of medications for opioid use disorder (MOUD) utilization. Provides qualitative feedback data from agency staff in Kentucky and discusses organizational, patient, and community factors that impact MOUD utilization. Includes perspectives from rural areas.
Author(s): Hannah K. Knudsen, Shaquita Andrews-Higgins, Sandra Back-Haddix, et al.
Citation: Substance Abuse Treatment, Prevention, and Policy, 20, 15
Date: 04/2025
view details
Examines perspectives from substance use treatment program staff related to the barriers and facilitators of medications for opioid use disorder (MOUD) utilization. Provides qualitative feedback data from agency staff in Kentucky and discusses organizational, patient, and community factors that impact MOUD utilization. Includes perspectives from rural areas.
Author(s): Hannah K. Knudsen, Shaquita Andrews-Higgins, Sandra Back-Haddix, et al.
Citation: Substance Abuse Treatment, Prevention, and Policy, 20, 15
Date: 04/2025
view details
Different Forms of Stigma and Rural Primary Care Professionals' Willingness to Prescribe Buprenorphine
Presents a study exploring the different types of stigma affecting buprenorphine and other medications for opioid use disorder (MOUD) prescribing rates in rural primary care settings. Details perceived stigmas around MOUD by providers, such as the fear of being harmed by patients, fear of their professional image being harmed, and the fear of the medications harming their patients.
Author(s): Berkeley Franz, Lindsay Y. Dhanani, Sean Bogart, et al.
Citation: Journal of Substance Use & Addiction Treatment, 171, 209633
Date: 04/2025
view details
Presents a study exploring the different types of stigma affecting buprenorphine and other medications for opioid use disorder (MOUD) prescribing rates in rural primary care settings. Details perceived stigmas around MOUD by providers, such as the fear of being harmed by patients, fear of their professional image being harmed, and the fear of the medications harming their patients.
Author(s): Berkeley Franz, Lindsay Y. Dhanani, Sean Bogart, et al.
Citation: Journal of Substance Use & Addiction Treatment, 171, 209633
Date: 04/2025
view details
Impact of Recent Methamphetamine Use on Treatment Outcomes Among Individuals Initiating Medications for Opioid Use Disorders in Rural Treatment Settings: A 1-Year Retrospective Cohort Study
Explores the predictive role that methamphetamine urinalysis (UA) results in rural MOUD treatment intake has on methamphetamine and opioid use over time. Discusses the rise of co-use of opioids and methamphetamine and explores indicators for clinicians providing MOUD treatment.
Author(s): Leslie A Kenefick, Lisa Khairy, Luke Hall, et al.
Citation: Rural and Remote Health, 25(2), 9536
Date: 04/2025
view details
Explores the predictive role that methamphetamine urinalysis (UA) results in rural MOUD treatment intake has on methamphetamine and opioid use over time. Discusses the rise of co-use of opioids and methamphetamine and explores indicators for clinicians providing MOUD treatment.
Author(s): Leslie A Kenefick, Lisa Khairy, Luke Hall, et al.
Citation: Rural and Remote Health, 25(2), 9536
Date: 04/2025
view details
Epidemiology of 911 Calls for Opioid Overdose in Nogales, Arizona
Presents a study reviewing the 911 calls pertaining to opioid overdose in the Nogales, AZ area. Details the prehospital care received in the rural, borderland community and evaluates EMS's adherence to naloxone distribution protocol.
Author(s): Melody Glenn, Darien Stratton, Keith Primeau, Amber Rice
Citation: Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health, 26(3)
Date: 03/2025
view details
Presents a study reviewing the 911 calls pertaining to opioid overdose in the Nogales, AZ area. Details the prehospital care received in the rural, borderland community and evaluates EMS's adherence to naloxone distribution protocol.
Author(s): Melody Glenn, Darien Stratton, Keith Primeau, Amber Rice
Citation: Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health, 26(3)
Date: 03/2025
view details
Comparative Effectiveness of Buprenorphine Adherence with Telemedicine Versus In-Person for Rural and Urban Patients
Compares adherence to buprenorphine for opioid use disorder in telemedicine versus in-person healthcare in rural and urban populations. Utilizes 2017–2022 data from 511 adults and compares 3,302 in-person and 519 telemedicine visits, with breakdowns according to patient characteristics, adherence, gaps in treatment, and rural versus urban location. Discusses changing legislative requirements related to buprenorphine treatment and the potential impact on rural populations.
Author(s): Thomas J. Reese, Nana Addo Padi-Adjirackor, Kevin N. Griffith, et al.
Citation: Journal of the American Pharmacists Association, 65(2), 102318
Date: 03/2025
view details
Compares adherence to buprenorphine for opioid use disorder in telemedicine versus in-person healthcare in rural and urban populations. Utilizes 2017–2022 data from 511 adults and compares 3,302 in-person and 519 telemedicine visits, with breakdowns according to patient characteristics, adherence, gaps in treatment, and rural versus urban location. Discusses changing legislative requirements related to buprenorphine treatment and the potential impact on rural populations.
Author(s): Thomas J. Reese, Nana Addo Padi-Adjirackor, Kevin N. Griffith, et al.
Citation: Journal of the American Pharmacists Association, 65(2), 102318
Date: 03/2025
view details
Drug Overdose Deaths: South Carolina, 2023
Reports drug overdose deaths for South Carolina in 2023 using state vital statistics data. Includes statistics on the demographics of drug-related mortality, unintentional and intentional deaths, drug categories, and selected drugs. Includes county-by-county tables and maps showing totals, rates, and change over time.
Date: 03/2025
Sponsoring organization: South Carolina Department of Public Health
view details
Reports drug overdose deaths for South Carolina in 2023 using state vital statistics data. Includes statistics on the demographics of drug-related mortality, unintentional and intentional deaths, drug categories, and selected drugs. Includes county-by-county tables and maps showing totals, rates, and change over time.
Date: 03/2025
Sponsoring organization: South Carolina Department of Public Health
view details
The Importance of Contextually Specific Support Relationships in Implementing Programs to Link People to Medication for Opioid Use Disorder (MOUD) Treatment During Reentry from County Jails
A case study that examines an intervention that links people in county jails to medication for opioid use disorder (MOUD) programs. Analyzes 3 rural and 2 urban county jails in Kentucky and the related program implementation, reach, and sustainability.
Author(s): Margaret McGladrey, Marisa Booty, Susannah Stitzer, et al.
Citation: Health & Justice volume 13, 20
Date: 03/2025
view details
A case study that examines an intervention that links people in county jails to medication for opioid use disorder (MOUD) programs. Analyzes 3 rural and 2 urban county jails in Kentucky and the related program implementation, reach, and sustainability.
Author(s): Margaret McGladrey, Marisa Booty, Susannah Stitzer, et al.
Citation: Health & Justice volume 13, 20
Date: 03/2025
view details